Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

323.02 (USD) • At close March 13, 2025
Bedrijfsnaam Madrigal Pharmaceuticals, Inc.
Symbool MDGL
Munteenheid USD
Prijs 323.02
Beurswaarde 7,132,346,204
Dividendpercentage 0%
52-weken bereik 189 - 377.46
Industrie Biotechnology
Sector Healthcare
CEO Mr. William J. Sibold
Website https://www.madrigalpharma.com

An error occurred while fetching data.

Over Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic

Vergelijkbare Aandelen

Atrion Corporation logo

Atrion Corporation

ATRI

459.92 USD

Cronos Group Inc. logo

Cronos Group Inc.

CRON

1.86 USD

Outset Medical, Inc. logo

Outset Medical, Inc.

OM

0.554 USD

RadNet, Inc. logo

RadNet, Inc.

RDNT

45.92 USD

Revolution Medicines, Inc. logo

Revolution Medicines, Inc.

RVMD

39.03 USD

Agios Pharmaceuticals, Inc. logo

Agios Pharmaceuticals, Inc.

AGIO

31.07 USD

NGM Biopharmaceuticals, Inc. logo

NGM Biopharmaceuticals, Inc.

NGM

1.54 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)